New eczema drug ZL-1503 enters first human safety trial

NCT ID NCT07235384

Recruiting now Disease control Sponsor: Zai Lab (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meaning some participants get the drug and some get a dummy pill, and neither they nor the doctors know who got what. The main goal is to check for side effects, not yet to see if it works for eczema.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZL-1503
What this could lead to: If this early trial shows ZL-1503 is safe, it could lead to a new treatment option for moderate to severe atopic dermatitis.
What could go wrong: This is a very early phase 1 study with only 84 participants, focused on safety. It is too soon to know if ZL-1503 will effectively treat atopic dermatitis or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Aotearoa Clinical Trials
RECRUITING

Auckland, Auckland, New Zealand
Hangzhou First People's Hospital
RECRUITING

Hangzhou, Zhejiang, China
Momentum Auckland
RECRUITING

Takapuna, Auckland, New Zealand
Momentum Hamilton
RECRUITING

Hamilton, Hamilton, New Zealand
Momentum Hutt Valley
RECRUITING

Upper Hutt, Wellington Region, New Zealand
Momentum Kapiti
RECRUITING

Waikanae, Wellington Region, New Zealand
Momentum Palmerston North
RECRUITING

Palmerston North, Mananwatu, New Zealand
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, China
Shandong Provincial Dermatology Hospital
RECRUITING

Jinan, Shandong, China
Shanghai Skin Disease Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Skin Health Institute
RECRUITING

Carlton, Victoria, Australia
Veracity Clinical Research
RECRUITING

Woolloongabba, Queensland, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.